Project IMPACT

«Thanks to the funding obtained from Horizon Europe, our research project aims to open up new therapeutic perspectives based on the results obtained from various disease models. This is an innovative and multidisciplinary project, whose success is strongly supported by the diverse but complementary expertise of partners from academic institutions and leading companies in the fields of computer science, biotechnology, and pharmaceuticals," says Professor Alessandra Rampazzo of the Department of Biology at the University of Padua and scientific coordinator of the international team. "Such collaboration will allow us to achieve our ambitious goals. The overall objective of the project funded by the European Community is to integrate and analyze clinical and molecular data from the ACM patient registry using artificial intelligence, along with data from structural and functional analyses of cellular models such as three-dimensional cardiac microtissues and in vivo models. These results will enable us to gain a better understanding of the role and impact of genetic alterations on the clinical progression of arrhythmogenic cardiomyopathy. Additionally," Alessandra Rampazzo concludes, "the project includes screening and subsequent evaluation of the therapeutic potential of several compounds and innovative molecules, both in cellular and animal models.»

«We are proud to be part of this ambitious research project about arrhythmogenic cardiomyopathy research project," says Franco Prampolini, Head of Advanced Industry Solutions at Lutech Group. At Lutech, we believe that the key to making significant progress in understanding and treating this serious cardiovascular disease is collaboration between partners with complementary skills. We are grateful to Horizon Europe for supporting this initiative, which will enable us to provide digital expertise and solutions for analyzing and understanding clinical data also through the use of artificial intelligence.»

The discovery of new therapeutic targets and an understanding of the underlying molecular mechanisms could not only lead to new therapies for ACM but could also pave the way for better clinical management of the disease and an improvement in the quality of life for patients.

The meeting of all participants, which will officially launch the project, will be held in Padua on October 26th and 27th.

Download the press release